Tarsus Pharmaceuticals (TARS)

• Market cap: $3.06B
• 1 day: -2.72%
• 5 days: 0.8%
• 1 month: 4.21%
• 3 months: -2.51%
• 6 months: -4.2%
• Year to date: -11.11%
• 1 year: 46.17%
• 5 years: 134.41%
• 10 years: 248.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Employees: 370